What's Happening?
The PreciseOnco research consortium, coordinated by Royal Philips, has been awarded EUR 14.9 million in funding from the EU's Innovative Health Initiative (IHI) to enhance precision cancer treatment. This
initiative aims to integrate advanced medical imaging, robotic guidance technologies, and AI to improve minimally invasive cancer therapies. The five-year program, with a total budget of EUR 23.9 million, includes five clinical studies to validate these technologies. The consortium seeks to set new standards for precision, safety, and efficiency in cancer care by leveraging spectral imaging and robotic systems to guide interventional instruments with high precision. The project will also explore electrochemotherapy, combining electrical pulses with chemotherapy to target cancer cells while preserving healthy tissue.
Why It's Important?
This initiative is significant as it addresses the growing global cancer burden, projected to reach over 35 million new cases by 2050. By advancing precision in cancer treatment, the consortium aims to improve patient outcomes and optimize hospital resources. The integration of AI and advanced imaging technologies could lead to more effective and less invasive cancer treatments, reducing recovery times and side effects compared to traditional surgery. The project also highlights the importance of public-private partnerships in driving healthcare innovation, potentially setting a new benchmark for cancer care across Europe and beyond.
What's Next?
The PreciseOnco consortium will conduct five clinical studies to validate the new technologies in real-world settings. These studies will focus on various cancer types and interventional workflows, aiming to generate evidence for the adoption of spectral imaging and robotic guidance in cancer centers. The project will also assess the health economic impact of these innovations, potentially influencing future healthcare policies and practices. As the consortium progresses, it may pave the way for broader access to advanced cancer treatments, benefiting a larger patient population.
